Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. by Bazan-Peregrino, M, Carlisle, R, Hernandez-Alcoceba, R, Iggo, R, Homicsko, K, Fisher, K, Halldén, G, Mautner, V, Shen, Y, Seymour, L

Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice by Leroy, B, Ballinger, M, Baran-Marszak, F, Bond, G, Braithwaite, A, Concin, N, Donehower, L, El-Deiry, W, Fenaux, P, Gaidano, G, Langerød, A, Hellstrom-Lindberg, E, Iggo, R, Lehmann-Che, J, Mai, P, Malkin, D, Moll, U, Myers, J, Nichols, K, Pospisilova, S, Ashton-Prolla, P, Rossi, D, Savage, S, Strong, L, Tonin, P, Zeillinger, R, Zenz, T, Fraumeni, J, Taschner, P, Hainaut, P, Soussi, T